Molina Healthcare at UBS Global Healthcare Conference - MOLINA HEALTHCARE INC

Explicit Guidance:

• 2026 Earnings: Building blocks target $9.50 EPS, derived from a $5.25 2026 base plus $4.00 embedded earnings; excludes legacy Medicaid MLR improvements (current guidance 92.6%; any improvement is upside).
• 2027 Embedded Earnings: Expectation to realize $4.00 of embedded earnings in 2027, composed of: $1.50 from Florida Kids contract moving from break-even to profitability; $1.00 from exiting MAPD (general issue Medicare) business which currently loses $1.00/share; and $1.50 from G&A leverage driven by $3B premium revenue growth ($42B to $45B).
• Remaining Embedded Earnings: The remaining $5.00 of the $9.00 embedded earnings target is scheduled for 2028 and 2029.
• Revenue Guidance: Premium revenue projected to grow to $45 billion in 2027 from $42 billion in 2026.
• MLR Targets: 2026 Medical Loss Ratio (MLR) guidance is 92.6%; 2027 outlook assumes 6% rate growth against 5.5%–6% medical cost trend.
• Earnings Seasonality: Historically, earnings are 55%–70% front-end loaded across the year.

Business-Segment Outlook:

• Medicaid: 2027 rate outlook is 6%, aiming to offset 5.5%–6% medical cost trend; core trend stabilized at 4.5%, with 1%–1.5% additional headwind from acuity mix shift due to 6% membership loss from OB3 work requirements.
• Medicare: Business will be strictly dual-eligible in 2027; growth driven by Enhanced Alignment Enrollment (EAE) which requires MCOs to hold both Medicaid and Medicare contracts, creating a structural advantage for integrated players.
• Florida Kids Contract: Implemented October 1st; Q4 expected to show $1.00/share loss (99% MLR) due to one-time startup costs; targeting break-even in 2027 (need to pick up 300 bps); majority of efficiency gains expected from medical cost line.
• Marketplace/ACA: Exiting 7 states for 2027 (likely 5 with meaningful local scale); segment currently loses $0.75/share but expected to reach break-even in 2027 due to rate adjustments; re-entry conditional on stable risk pool and local scale.
• Backlog/Implementation: Georgia and Texas Medicaid awards (originally 2027) may be delayed; pushed conservative assumptions to 2028 revenue build; readiness costs and capital commitments are known and manageable.

Market and Competitive Outlook:

• Competitive Dynamics: Increased state reliance on referenceability (calling other states to verify performance) favors Molina's track record; 90% re-procurement retention and 80% new procurement win rate.
• Market Structure: Anticipate states moving from weak to strong form EAE, increasing barriers to entry for Medicare-only players and favoring dual-eligible integrated models.
• CSNP Impact: C-SNPs viewed as a workaround for players without Medicaid contracts in dual-eligible markets; expected to lose relevance as states prioritize integrated models.
• Pricing/Trends: Most markets underfunded by ~300 bps; states expected to adjust rates to catch up on underfunding and absorb higher core trend.

Macro / Industry Outlook:

• OB3/Work Requirements: 2027 assumes 6% membership decline; implementation delayed to May 1st in plaintiff states; Massachusetts vs. Oz litigation suggests states will have more flexibility in defining frailty, creating a "softer landing" for disenrollment.
• Political Environment: "Blue tidal wave" in recent elections; potential for gridlock due to lack of 60-seat Senate supermajority; bipartisan support expected for pharmacy transparency and No Surprises Act; Democratic governors may ease work requirements but funding constraints for Medicaid expansion remain a challenge.
• Regulation: CMS struck down medical frailty rule (viewed as less onerous); states now have 6 months to document frailty before termination.

Strategic Initiatives:

• Cost Efficiency: Executing $1.50/share G&A efficiency driven by scaling revenue to $45B in 2027; disciplined management of fixed vs. variable costs.
• M&A Pipeline: Pipeline active with struggling non-profits; focus on turnaround situations and distressed assets; no capital constraints ($600M cash at parent, Debt-to-Cap <45%).
• Capital Allocation: Pecking order remains: 1. Organic growth (targeting 50% ROE), 2. M&A (targeting close to organic multiples), 3. Share repurchases (only after capital is deployed).
• Long-term Targets: Optimistic to reach 2.5% target margins during the strategic planning period.

Risks and Headwinds to Outlook:

• Membership Volatility: 6% membership headwind in 2027 due to OB3 work rules; uncertainty remains on final impact and potential follow-on effects in 2028.
• Regulatory Exposure: California undocumented immigration status members reverting to fee-for-service in 2027 projected to be $0.20–$0.25/share headwind.
• Market Instability: ACA risk pool volatility (changing subsidies, rules, enrollment periods) remains a primary constraint for Marketplace re-entry.
• Implementation Risks: New contracts (e.g., Florida Kids) face typical startup inefficiencies and ramp-up delays in medical and G&A efficiency.
• Rate/Trend Imbalance: Any divergence where medical trend exceeds 6% rate growth will negatively impact MLR and margins.

Management Tone on the Future:

• Confidence Level: "Cautious optimism" regarding the positive turn, specifically citing improved environment for work requirements and rate/trend dynamics.
• Guidance Status: Explicitly states current building blocks are not formal guidance; full earnings guidance to be provided in February.
• Outlook vs. Peers: Emphasizes ability to generate positive net income (1%–1.5% margin) while competitors lose money; confidence in outperforming market by 300 bps on new contracts.
• Trend: Views 2026 as a trough with improvement expected in 2027; expects a glide path to $9.50+ EPS as legacy issues resolve and new leverage kicks in.

Miscellaneous:

• Capital Structure: Parent company holds $600 million in cash, growing with subsidiary dividends; Debt-to-Cap under 45%; not capital constrained for growth.
• EAE Mechanics: Strong form EAE creates a natural barrier to entry; states enforcing EAE are expected to increase, favoring integrated Medicaid/Medicare providers.
• State Negotiations: 80% of rate determinations (covering 55% of revenues effective Jan 1) are in draft or final form; some states already pricing in acuity shift adjustments.